Stockreport

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

IN8bio, Inc.  (INAB) 
PDF 100% of acute myeloid leukemia (AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML p [Read more]